PH II STUDY RECOMBINANT PLATELET ACTIVATING FACTOR ACETYLHYDROLASE

胰腺炎是内镜逆行胰胆管造影术（ERCP）最常见的严重并发症。 没有有效的方法来预防ERCP术后胰腺炎。 血小板活化因子（PAF）是实验性胰腺炎早期重要的炎症介质。 内源性地，它被PAF-乙酰水解酶降解。 PAF-AH，外源性给药，已被证明可以减轻实验性胰腺炎的损伤。 重组PAF-AH已被用于人类，并且似乎是安全的。 我们计划在一项双盲、安慰剂对照、前瞻性试验中研究rPAF-AH预防ERCP术后胰腺炎的作用。

Pancreatitis is the most common significant complication of endoscropy retrograde cholangiopancreatography (ERCP). There are no effective modalities to prevent post-ERCP pancreatitis. Platelet activating factor (PAF) has been shown to be an important early inflammatory mediator in experimental pancreatitis. Endogenously, it is degraded by PAF- acetyl hydrolase. PAF-AH, given exogenously, has been shown to attenuate injury in experimental pancreatitis. A recombinant PAF-AH has been given to humans and appears to be safe. We plan to study rPAF-AH in preventing post-ERCP pancreatitis in a double-blinded, placebo controlled, prospective trial.